Press Release Archives | Page 2 of 3 | CereVasc | Neurological Disease Device Company

18 Sep, 2023

CereVasc Receives FDA IDE Approval to Expand its Clinical Study of Patients with Normal Pressure Hydrocephalus Utilizing the Generation 2 eShunt® System

Admin2023-11-06T22:46:27+00:00September 18th, 2023|

13 Sep, 2023

CereVasc eShunt® System Study Data Presented at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress in Marseille

Admin2023-11-06T22:43:59+00:00September 13th, 2023|

26 Jun, 2023

CereVasc & LianMedical Announce Corporate Partnership

Admin2023-11-06T22:31:47+00:00June 26th, 2023|

14 Jun, 2023

CereVasc’s Minimally Invasive Central Nervous System Therapy Delivery System Receives Outstanding Presentation Award at American Society of Gene & Cell Therapy Annual Meeting

Admin2023-11-06T22:29:02+00:00June 14th, 2023|

04 May, 2023

CereVasc to Present Data on its Minimally Invasive CNS Delivery System at Upcoming American Society of Gene and Cell Therapy Annual Meeting

Admin2023-11-06T22:08:22+00:00May 4th, 2023|

28 Mar, 2023

CereVasc Appoints Dr. Adel Malek Chief Medical Officer

Admin2023-11-06T22:03:27+00:00March 28th, 2023|

21 Nov, 2022

Tufts Medical Center Neurosurgeons and CereVasc Co-founders Honored by the Society of Vascular and Interventional Neurology for Innovation in Hydrocephalus Treatment

Admin2023-11-06T21:59:07+00:00November 21st, 2022|

29 Aug, 2022

CereVasc Announces First Patient Treated in U.S. Pilot Trial Evaluating the eShunt System in Patients with Normal Pressure Hydrocephalus

Admin2023-11-06T21:52:45+00:00August 29th, 2022|

09 Aug, 2022

CereVasc Announces FDA Approval of Second IDE Study of the eShunt® System

Admin2023-11-06T21:48:30+00:00August 9th, 2022|

25 Apr, 2022

First patient treated in CereVasc® clinical trial of eShunt® System for Normal Pressure Hydrocephalus

Admin2023-11-06T21:37:10+00:00April 25th, 2022|